Carter Ledyard attorneys Mary Brown and Steven Glusband successfully represented Trinity Biotech (Nasdaq: TRIB) in a series of transactions with funds managed by Perceptive Advisors. The transactions include an amendment to the company’s Credit Agreement to provide for $5 million of additional term-loan funding, among other things, and agreements that allow certain obligations of the company and its subsidiaries to be converted into equity.
These transactions enhance the Trinity Biotech’s financial capacity and operational flexibility transactions in support of its ongoing and future growth projects to deliver advanced diagnostic and diabetes management solutions. The newly executed agreements also position Trinity Biotech to advance its long-term growth agenda while supporting a further reduction in overall debt.